Study on Initiation and Immunological Mechanism of Childbirth

Pregnancy Clinical Trial

Official title:

Study on the Initiation and Immunological Mechanism of Parturition

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05604768
• Other study ID #: KY2022-03
• Status: Recruiting
• Start date: March 28, 2022
• Est. completion date: March 28, 2025

Study information

• Verified date: October 2022
• Source: Beijing Ditan Hospital
• Contact: Wei Yi, Doctor
• Phone: 13683687062
• Email: yiwei1215[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is a prospective observational study. The participants including 40 pregnant women who have been filed and delivered in our hospital will enrolled, collect venous blood will be collected at different stages of pregnancy, delivery, postpartum to detect the concentration of fetal free DNA, the frequency of associated immune cells, and the expression of functional molecules, so as to explore the immunological mechanism of delivery initiation.

Description:

This study is a prospective observational study. The participants including 40 pregnant women (20 normal parturients and 20 pregnant women with threatened preterm delivery) who have been filed and delivered in our hospital will enrolled, collect venous blood will be collected before 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, during parturition, and at 42 days after delivery to conduct the following research: 1) Studying the frequency of peripheral blood MDSCs, pDC and NK cells and the expression of functional molecules at different stages of pregnancy (12,24,36 weeks of pregnancy), before delivery and 42 days after delivery through the expression of relevant functional molecules. 2) Detecting the levels of cytokines and chemokines in peripheral blood at different stages of pregnancy (12,24,36 weeks of pregnancy), before delivery and 42 days after delivery, including: IL-1 β, IL-6, IL-10, IL-18, TGF- β and TNF- α, GM-CSF , IL-23, IL-17, IL-13, IL-4, IL-2, IFN-, IFN-, IL-8, GRO α, GCSF, GMCSM, CCL2, CCL5, CCL26,CXCL8, CXCL12，PGE2, M-CSF, COX2, CCL3, CCL4, CXCL1, IDO, Arg-1, ROS and NO. 3) Detection of cffDNA concentration in peripheral blood at different stages of pregnancy (12,24,36 weeks of pregnancy), before delivery and 42 days after delivery. 4) Detection of frequency of MDSCs, pDC and NK cells and expression of functional molecules in placenta. 5) Frequency of peripheral blood MDSCs, pDC and NK cells, expression of functional molecules, cytokine level and cffDNA concentration in pregnant women with threatened preterm labor. 6) Collecting and studying the demographic data of pregnant women at different stages of pregnancy (12,24,36 weeks of pregnancy), before delivery and 42 days after delivery, adverse events of mothers and infants in the perinatal period, and auxiliary examination data (blood routine test, liver and kidney function, TSH, infection index of Aimei B and C, TSH, blood glucose, blood coagulation function, estrogen and progesterone levels, ultrasound, electrocardiogram, etc).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: March 28, 2025
• Est. primary completion date: March 28, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• 20 normal parturients and 20 pregnant women with threatened preterm labor who had undergone antenatal examination and delivery in Beijing Ditan Hospital were fully informed of the risks and volunteered to join the study and signed the informed consent form.

Exclusion Criteria:

• 1. Combined with HCV, HIV, syphilis or other infectious diseases.

• 2. Chronic diseases such as diabetes, hypertension, thyroid disease and autoimmune disease.

• 3. Both husband and wife or their families have delivered congenital abnormal fetus in the past.

• 4. Either spouse is unwilling to participate in this study.

Related Conditions & MeSH terms

• Pregnancy

Locations

Country	Name	City	State
China	Beijing Ditan Hospital, Capital Medical University	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Ditan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The change of the frequency of myeloid-derived suppressor cells (MDSCs) in normal pregnancy and delivery	The frequency of MDSCs in maternal blood and placenta during normal pregnancy and delivery.	at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
Primary	The change of functional molecules expression of myeloid-derived suppressor cells (MDSCs) in normal pregnancy and delivery	The expression of functional molecules of MDSCs in maternal blood and placenta during normal pregnancy and delivery.	at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
Primary	The change of the frequency of plasmacytoid dendritic cells (pDC) in normal pregnancy and delivery	The frequency of pDC in maternal blood and placenta during normal pregnancy and delivery.	at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
Primary	The change of the functional molecules expression of plasmacytoid dendritic cells (pDC) in normal pregnancy and delivery	The expression of functional molecules of pDC in maternal blood and placenta during normal pregnancy and delivery.	at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
Primary	The change of the frequency of Nature Killer (NK) cells in normal pregnancy and delivery	The frequency of NK cells in maternal blood and placenta during normal pregnancy and delivery.	at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
Primary	The change of the functional molecules expression of Nature Killer (NK) cells in normal pregnancy and delivery	The expression of functional molecules of NK cells in maternal blood and placenta during normal pregnancy and delivery.	at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
Primary	The change of the content of cffDNA in normal pregnancy and delivery	The content of cffDNA in maternal blood and placenta during normal pregnancy and delivery.	at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
Secondary	The change of the frequency of myeloid-derived suppressor cells (MDSCs) in Pregnant women with threatened premature delivery	The frequency of MDSCs in maternal blood and placenta in Pregnant women with threatened premature delivery.	at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
Secondary	The change of functional molecules expression of myeloid-derived suppressor cells (MDSCs) in Pregnant women with threatened premature delivery	The expression of functional molecules of MDSCs in maternal blood and placenta in Pregnant women with threatened premature delivery.	at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
Secondary	The change of the frequency of plasmacytoid dendritic cells (pDC) in Pregnant women with threatened premature delivery	The frequency of pDC in maternal blood and placenta in Pregnant women with threatened premature delivery.	at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
Secondary	The change of functional molecules expression of plasmacytoid dendritic cells (pDC) in Pregnant women with threatened premature delivery	The expression of functional molecules of pDC in maternal blood and placenta in Pregnant women with threatened premature delivery.	at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
Secondary	The change of frequency of Nature Killer (NK) cells in Pregnant women with threatened premature delivery	The frequency of NK cells in maternal blood and placenta in Pregnant women with threatened premature delivery.	at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
Secondary	The change of functional molecules expression of Nature Killer (NK) cells in Pregnant women with threatened premature delivery	The expression of functional molecules of NK cells in maternal blood and placenta in Pregnant women with threatened premature delivery.	at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery
Secondary	The change of the content of cffDNA in Pregnant women with threatened premature delivery	The content of cffDNA in maternal blood and placenta in Pregnant women with threatened premature delivery.	at 12 weeks of pregnancy, at 24 weeks of pregnancy, at 36 weeks of pregnancy, at parturition, and at 42 days after delivery